A symBIONT, literally, is an organism in symbiosis: a living thing that survives through reciprocity. We borrowed the word for our masthead because it describes life sciences better than any other word could. Medicine has a visible half: available by prescription or through a physician’s intervention. Then there’s the other half, the scaffold without which the visible half cannot exist. The research that led to the molecule. The cleanroom in which the drug is made. The sterile process equipment that is used to fill the vials. The cold chain it traverses to get to pharmacies and hospitals. The people who keep all of it within specification, batch after batch. The invisible half.
To us, symBIONTs are the people and companies building the capability, infrastructure, technologies, and systems that advance human and animal health.
For our first edition, we chose pharma. Partly because it is where the relationship is easiest to see, and partly as a nod to my own first steps in pharma media many years ago. This is a homecoming of sorts, and I owe a debt to my wonderful friends at Pharmabiz.com for their generous helping hand with the reboot.
My time in pharma media taught me which stories grab eyeballs. Drug prices. Patents. A humanitarian crisis when something breaks, a miracle when something works. The medicine itself arrives in every story fully formed, as if it travelled from lab bench to pharmacy shelf on its own. The work between those headlines, the unglamorous middle where medicine is actually made, almost never gets attention. We wanted everyone in this edition of symBIONT to answer a different question with their working lives: what does it take to make a medicine the world can trust, every batch, every time?
So that’s who we went looking for.
Like Safwa, who champions organisational culture as the overlooked cornerstone of strategy.
like Pharmaconex, the Cairo gathering designed to meet Africa’s biopharma moment and amplify it to the world,
like Vishal, who shows that building in emerging markets is as much about nurturing people and trust as it is about molecules and machines,
like Prachi, who chose cleanroom flooring, an unglamorous niche, and turned it into a critical safeguard for compliance and patient safety, and
like Jackey, who is building Pharmaclick, a mobile-first platform to consolidate the fragmented information pathways that connect India’s pharma industry.
Each one of our Linchpins here shows us a path forward for the future of life sciences in underinvested geographies.
We hope you enjoy getting to know them as much as we did.
– Karina
